Skip to main navigation
Skip to search
Skip to main content
Johns Hopkins University Home
Home
Profiles
Research units
Research output
Search by expertise, name or affiliation
Early antibody treatment, inflammation, and risk of post-COVID conditions
CSSC-004 Consortium
School of Medicine
Bloomberg School of Public Health
Research output
:
Contribution to journal
›
Article
›
peer-review
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Early antibody treatment, inflammation, and risk of post-COVID conditions'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Inflammation
100%
Antibody Treatment
100%
Post-COVID-19 Condition
100%
Convalescent Plasma Therapy
25%
Adjusted Odds Ratio
18%
Cytokine Levels
18%
Female Sex
12%
Interleukin-6
12%
Symptom Onset
12%
COVID-19
12%
COVID-19 Convalescent Plasma
12%
Clinical Characteristics
6%
Day 14
6%
Type 1 Diabetes Mellitus (T1DM)
6%
Risk Factors
6%
Old Age
6%
Early Treatment
6%
Demographic Characteristics
6%
Randomized Trial
6%
Randomized Clinical Trial
6%
Obesity
6%
Chemokines
6%
Age of Infection
6%
Multivariate Logistic Regression Model
6%
Multivariable
6%
Age-adjusted
6%
Early Intervention
6%
Treatment Study
6%
Long-term Health Effects
6%
Biospecimens
6%
Multiplexing
6%
Advancing Age
6%
Anosmia
6%
Early Biomarker
6%
Intervention Therapy
6%
Sandwich Immunoassay
6%
Meso Scale Discovery
6%
Symptom Reporting
6%
Anti-IL-6 Therapy
6%
SARS-CoV-2 Infection
6%
Pharmacology, Toxicology and Pharmaceutical Science
Inflammation
100%
Convalescence
100%
Symptom
83%
Cytokine
66%
SARS Coronavirus
50%
Infection
33%
Diabetes Mellitus
16%
Randomized Clinical Trial
16%
Chemokine
16%
Biological Marker
16%
Immunoassay
16%
Anosmia
16%
Immunology and Microbiology
Blood Plasma
100%
Cytokine
57%
Interleukin-6
42%
Severe Acute Respiratory Syndrome Coronavirus 2
42%
COVID-19
28%
Chemokine
14%
Immunoassay
14%
Psychology
Regression Model
100%
Early Intervention
100%
Mathematics
Odds Ratio
100%
Logistic Regression Model
33%
Randomized Trial
33%
Baseline Level
33%
Neuroscience
Anti-IL-6
33%